As we reach the end of Lung Cancer Awareness month, we thought it was particularly timely to talk about occupational lung disease and the responsibilities that employers have to mitigate and reduce related risks.
According to Cancer Research, lung cancer is the third most common type of cancer in the UK (behind breast cancer and prostate cancer), it is also the most fatal, contributing to a fifth (21%) of all cancer deaths in the UK in 2018.
The latest statistics from the HSE show that there are an estimated 12,000 deaths per year related to lung diseases that are linked to past exposures in the workplace. The real number may be much higher – measurement is difficult to track as many lung diseases having a long latency period, meaning they start to develop many years after the workplace exposures that caused them or contributed. The main exceptions are occupational asthma and allergic alveolitis which can develop more quickly.
Current and recently occurring cases of long-latency diseases are mainly a reflection of past workplace conditions. However, many of the causative agents can still be present in workplaces and thus constitute a potential ongoing hazard.
Breathing in specks of dust, gases, fumes and vapours in the workplace can cause serious, long-term lung damage and often incurable health problems. Occupational lung diseases include but are not limited to:
- Work-related asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Work-related lung cancer
- Pneumoconiosis
- Silicosis
- Asbestos-related disease
- Extrinsic allergic alveolitis
By law, employers are required to control exposure in all uses by site and process-specific measures. Risk reduction/mitigation methods include:
- Competent assessments and ongoing reviews
- Monitoring / Surveys
- Alternative processes
- Less hazardous materials
- Relevant training and substance handling
- Enclosures/effective ventilation
- Protective equipment – as a last resort
- Occupational Health Monitoring
- The important thing is to ensure the activity and those who could be exposed are below regulatory workplace exposure limits (WELs)
How can you recognise the signs and symptoms of lung cancer?
There are usually no signs or symptoms in the early stages. Symptoms of lung cancer develop as the condition progresses. The main symptoms include:
- A cough that doesn’t go away after 2 or 3 weeks
- A long-standing cough that gets worse
- Chest infections that keep coming back
- Coughing up blood
- An ache or pain when breathing or coughing
- Persistent breathlessness
- Persistent tiredness or lack of energy
- Loss of appetite or unexplained weight loss
As for the causes, smoking is the biggest risk factor for lung cancer, being accountable for more than 70% of cases, the other main causes include pollution and occupational exposure.
How can AssessNET help organisations to discharge their statutory responsibilities?
The AssessNET COSHH and SDS tool helps you to assess the risks associated with specific activities and exposure levels. It enables you to review current control measures in place and assist in highlighting any alternative safer products that can be used. The solution also provides recommendations regarding relevant PPE equipment and any emergency procedures necessary based on SDS data. The built-in SDS manager allows you to tailor your COSHH assessments to your operations, giving you visibility of the risks created by using certain products and guidance on how to control them.
Built with efficiency at its core; AssessNET’s SDS management tool will notify owners of COSHH assessments and recommend reviews when substance changes are made and a new edition of the SDS is published on the platform. Combined with AssessNET’s powerful Task Manager at its core, linkages to EH40, glove permeation data and location-specific registers, AssessNET can provide a robust and automated solution across your organisation.
Latest News
Riskex Limited
100 Avebury Boulevard
Central Milton Keynes
Buckinghamshire
MK9 1FH
What3words reference:
Contact us
Make an enquiry:
Company No. 05174302
VAT No. 844 5092 22
Archive
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- May 2020
- April 2020
- March 2020
- January 2020
- August 2019
- July 2019
- June 2019
- April 2019
- March 2019
- February 2019
- October 2018
- June 2018
- May 2018
- April 2018
- March 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- July 2017
- June 2017
- May 2017
- April 2017